Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
M MUSCULO-SKELETAL SYSTEM
M03 MUSCLE RELAXANTS
M03C MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS
M03CA Dantrolene and derivatives
M03CA01 Dantrolene
D02274 Dantrolene sodium (USP) <JP/US>
USP drug classification [BR:br08302]
Antispasticity Agents
Dantrolene
D02274 Dantrolene sodium (USP)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
12 Agents affecting peripheral nervous system
122 Skeletal muscle relaxants
1229 Others
D02274 Dantrolene sodium (USP); Dantrolene sodium hydrate (JP18)
Drug groups [BR:br08330]
Musculo-skeletal system agent
DG02029 Muscle relaxant
DG00778 Dantrolene
D02274 Dantrolene sodium
Metabolizing enzyme substrate
DG01891 CYP1A1 substrate
DG00778 Dantrolene
D02274 Dantrolene sodium
DG01892 CYP1A2 substrate
DG00778 Dantrolene
D02274 Dantrolene sodium
DG01633 CYP3A/CYP3A4 substrate
DG00778 Dantrolene
D02274 Dantrolene sodium
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D02274 Dantrolene sodium hydrate
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D02274
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D02274
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D02274
Drug groups [BR:br08330]
Musculo-skeletal system agent
DG02029 Muscle relaxant
DG00778 Dantrolene
Metabolizing enzyme substrate
DG01891 CYP1A1 substrate
DG00778 Dantrolene
DG01892 CYP1A2 substrate
DG00778 Dantrolene
DG01633 CYP3A/CYP3A4 substrate
DG00778 Dantrolene